Plant to prescription
Medicines whose starting molecule came from a plant, a fungus or a marine animal, with the approval dates, labeled uses and sales figures from the regulator or the company filing. Many are now made by semi-synthesis, synthesis or fermentation; the organism supplied the lead.
GAO-03-829 (June 2003), p. 4; Newman DJ, Cragg GM. J Nat Prod 2020;83:770–803, abstract; FDA, “What is a Botanical Drug?” (content current as of September 3, 2026); Ther Innov Regul Sci 2025 (FDA authors); Nobel Assembly press release, October 5, 2015.
Status. EUTECNIQ is in formation and has no laboratory, products or drug programs. This page records what regulators, companies and historians have published about other people's medicines. Nothing here is medical advice; indications are summarized from the current US label.
Related: History of botanical medicine · The claims gap · Pipeline · Bioactive compounds
Thirty-two milestones, 1805 to 2023
Each row is a dated event: an isolation or discovery reported in a peer-reviewed history, a Nobel Prize, or an original approval in Drugs@FDA (FDA) or by the European Commission (EU). Choose a source organism to bring its rows forward.
Organism, compound and approved drug
Twenty-two approved medicines, each traced to its source organism. The approval column gives the original approval of the named application in Drugs@FDA, or the European Commission date for the EU. The indication column summarizes the current US label, which is often broader than the first approval.
| Organism | Compound | Drug (brand) | First approval (agency, year) | Indication, current US label (summary) | Source |
|---|---|---|---|---|---|
| Plants | |||||
| Taxus brevifolia (bark of the original isolation) | Paclitaxel | Taxol | FDA, 1992 (NDA 020262) | Advanced ovarian carcinoma; adjuvant node-positive breast cancer; breast cancer after failed combination chemotherapy; first-line non-small cell lung cancer with cisplatin; second-line AIDS-related Kaposi's sarcoma | Drugs@FDA; paclitaxel label; Wall 1998 |
| Catharanthus roseus | Vincristine | Oncovin | FDA, 1963 (NDA 014103) | Acute leukemia; combination use in Hodgkin's disease, non-Hodgkin lymphomas, rhabdomyosarcoma, neuroblastoma, Wilms' tumor | Drugs@FDA; vincristine label |
| Catharanthus roseus | Vinblastine | Velban | FDA, 1965 (NDA 012665) | Palliative treatment of Hodgkin's disease, lymphomas, testicular carcinoma, Kaposi's sarcoma and other listed malignancies | Drugs@FDA; vinblastine label |
| Digitalis lanata (leaf) | Digoxin | Lanoxin | FDA, 1954 (NDA 009330) | Mild to moderate heart failure in adults; heart failure in children; ventricular rate control in chronic atrial fibrillation | Drugs@FDA; Lanoxin label |
| Galega officinalis (galegine lineage) | Metformin (synthetic biguanide) | Glucophage | FDA, 1995 (NDA 020357) | Glycemic control in type 2 diabetes, adults and children 10 years and older | Drugs@FDA; metformin label; Bailey 2017; Hadden 2005 |
| Artemisia annua | Artemether (artemisinin derivative) with lumefantrine | Coartem | FDA, 2009 (NDA 022268) | Acute, uncomplicated Plasmodium falciparum malaria, patients 2 months and older and at least 5 kg | Drugs@FDA; Coartem label |
| Cinchona bark | Quinine | Qualaquin | FDA, 2005 (NDA 021799) | Uncomplicated P. falciparum malaria only; label excludes nocturnal leg cramps | Drugs@FDA; quinine sulfate label; Achan 2011 |
| Galanthus and other Amaryllidaceae | Galantamine | Razadyne | FDA, 2001 (NDA 021169) | Mild to moderate dementia of the Alzheimer's type | Drugs@FDA; galantamine label; Heinrich 2010 |
| Colchicum autumnale | Colchicine | Colcrys | FDA, 2009 (NDA 022352) | Prophylaxis and treatment of gout flares in adults; familial Mediterranean fever, age 4 and older | Drugs@FDA; Colcrys label; Dasgeb 2018 |
| Podophyllin-yielding plants | Etoposide (from podophyllotoxin) | VePesid | FDA, 1983 (NDA 018768) | Refractory testicular tumors; first-line small cell lung cancer, in combination | Drugs@FDA; etoposide label; Hande 1998 |
| Camptotheca acuminata | Topotecan (camptothecin analogue) | Hycamtin | FDA, 1996 (NDA 020671) | Injection: metastatic ovarian cancer after progression on or after chemotherapy; platinum-sensitive small cell lung cancer that progressed at least 60 days after first-line chemotherapy; stage IV-B, recurrent or persistent cervical cancer, with cisplatin | Drugs@FDA; Hycamtin label; Wall 1998 |
| Camptotheca acuminata | Irinotecan (camptothecin analogue) | Camptosar | FDA, 1996 (NDA 020571) | Metastatic colorectal carcinoma, first-line with 5-FU and leucovorin, or after fluorouracil-based therapy | Drugs@FDA; Camptosar label; Wall 1998 |
| Chili peppers | Capsaicin (synthetic equivalent) | Qutenza | FDA, 2009 (NDA 022395) | Neuropathic pain of postherpetic neuralgia and of diabetic peripheral neuropathy of the feet, adults | Drugs@FDA; Qutenza label |
| Cannabis sativa | Cannabidiol | Epidiolex | FDA, 2018 (NDA 210365) | Seizures of Lennox-Gastaut syndrome, Dravet syndrome or tuberous sclerosis complex, age 1 and older | Drugs@FDA; Epidiolex label |
| Camellia sinensis (leaf) | Sinecatechins (botanical drug substance) | Veregen | FDA, 2006 (NDA 021902) | External genital and perianal warts, immunocompetent patients 18 and older | Drugs@FDA; Veregen label |
| Croton lechleri (red latex) | Crofelemer (botanical drug substance) | Mytesi | FDA, 2012 (NDA 202292) | Symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy | Drugs@FDA; Mytesi label |
| Ananas comosus (stem) | Anacaulase-bcdb (botanical drug substance) | NexoBrid | FDA, 2022 (BLA 761192) | Eschar removal in deep partial-thickness and full-thickness thermal burns | Drugs@FDA; NexoBrid label |
| Betula pendula, B. pubescens (bark) | Birch triterpenes (botanical drug substance) | Filsuvez | FDA, 2023 (NDA 215064) | Wounds of dystrophic and junctional epidermolysis bullosa, age 6 months and older | Drugs@FDA; Filsuvez label |
| Fungi | |||||
| Aspergillus terreus (also Monascus ruber, as monacolin K) | Lovastatin | Mevacor | FDA, 1987 (NDA 019643) | Dyslipidemia; reduction of coronary heart disease risk, with diet | Drugs@FDA; lovastatin label; Endo 2010 |
| Beauveria nivea | Cyclosporine | Sandimmune | FDA, 1983 (NDA 050573) | Prophylaxis of organ rejection in kidney, liver and heart transplants, with corticosteroids | Drugs@FDA; Sandimmune label |
| Marine organisms | |||||
| Tunicate (sea squirt) | Trabectedin (synthetic) | Yondelis | EU, 2007; FDA, 2015 (NDA 207953) | Unresectable or metastatic liposarcoma or leiomyosarcoma after an anthracycline | EMA EPAR; Drugs@FDA; Yondelis label |
| Conus magus (cone snail) | Ziconotide (synthetic conopeptide) | Prialt | FDA, 2004 (NDA 021060) | Severe chronic pain needing intrathecal therapy, when other treatment fails or is not tolerated | Drugs@FDA; Prialt label |
| Halichondria okadai (sponge) | Eribulin (synthetic halichondrin B analogue) | Halaven | FDA, 2010 (NDA 201532) | Metastatic breast cancer after two or more regimens; unresectable or metastatic liposarcoma | Drugs@FDA; Halaven label |
Drugs@FDA application overview pages and the current labels on DailyMed (openFDA label records), opened October 28, 2026. Heinrich M. Alkaloids Chem Biol 2010;68:157–165 (galantamine). Hande KR. Eur J Cancer 1998;34:1514–1521 (etoposide). Several originator brands are discontinued; generic labels were used where the brand label is no longer posted. EU trabectedin indications (soft-tissue sarcoma; relapsed platinum-sensitive ovarian cancer with pegylated liposomal doxorubicin): EMA EPAR.
Artemisinin and an extraction step
Tu Youyou's group screened herbal remedies in malaria-infected animals. An Artemisia annua extract gave 12–40% parasite inhibition, inconsistently. A recipe by Ge Hong described taking the juice of the leaves with cold water rather than by boiling; Tu switched from ethanol to a cold ether extraction and obtained 100% parasite killing in infected mice and monkeys.
The active component, artemisinin, was isolated and its structure established afterward. The first FDA-approved product containing an artemisinin derivative in this table is artemether–lumefantrine (2009).
| Year | Step | Record |
|---|---|---|
| 1969 | Tu Youyou heads a group in the national malaria project (Project 523) | Peer-reviewed histories (source line) |
| 1971 | Antimalarial activity of A. annua extracts | Peer-reviewed histories |
| 1972 | Artemisinin purified | Peer-reviewed histories |
| 2009 | Artemether–lumefantrine (Coartem) approved, uncomplicated P. falciparum malaria | Drugs@FDA, NDA 022268 |
| 2011 | Lasker Award to Tu Youyou | Peer-reviewed histories |
| 2015 | Half of the Nobel Prize in Physiology or Medicine, “for her discoveries concerning a novel therapy against Malaria” | Nobel Assembly, October 5, 2015 |
Nobel Assembly at Karolinska Institutet, press release and scientific background, 2015 (12–40% inhibition; Ge Hong; cold ether extraction; 100% in mice and monkeys). Liu W, Liu Y. Cardiovasc Diagn Ther 2016;6:1–2, and [authors, title, journal, year;volume:pages] (PMC6139675) (dates for 1969, 1971, 1972 and the 2011 Lasker Award). The Nobel background dates Ge Hong's recipes to 340 AD. The other half of the 2015 prize went to William C. Campbell and Satoshi Ōmura for avermectin.
Paclitaxel, supply and sales
Paclitaxel was isolated from Taxus brevifolia. FDA approved Taxol on December 29, 1992, for ovarian cancer after failure of first-line or later chemotherapy, and in 1994 for breast cancer. Bristol-Myers Squibb's 1996 annual report credited “a semi-synthetic material” with lower production costs; a current generic label states that paclitaxel is obtained by a semi-synthetic process from Taxus baccata.
Sales passed $1 billion in 1998 and fell 25% in 2001, when the company attributed the decline to generic competition.
| Measure (GAO-03-829) | Value |
|---|---|
| BMS worldwide Taxol sales, 1993 through 2002 | Over $9 billion |
| BMS's stated cost to develop Taxol | $1 billion (company officials) |
| Medicare payments for Taxol, 1994 through 1999 | $687 million |
| NIH royalty payments through 2002 | $35 million |
| Florida State University royalty rate (GAO estimate) | About 4.2% of worldwide sales |
US General Accounting Office. Technology Transfer: NIH–Private Sector Partnership in the Development of Taxol. GAO-03-829, June 4, 2003, p. 4 and p. 13, footnote 17. Wall ME. Med Res Rev 1998;18:299–314 (isolation from T. brevifolia). BMS Form 10-K FY1996 (1992 and 1994 US clearances; semi-synthetic material). Paclitaxel injection label, ANDA 216874 (T. baccata).
Old remedies, later approvals
Several plant medicines were isolated or in use long before modern drug approval. FDA's records show what happened later: Lanoxin tablets (1997) and Colcrys (2009) were approved as “Type 7 – drug already marketed without approved NDA,” the category for products sold before an application was approved.
| Plant | Compound | Early record | Approval record |
|---|---|---|---|
| Opium poppy | Morphine | Sertürner reported a sleep-inducing crystalline substance from poppy juice in 1805; his work led to the isolation of other alkaloids, codeine among them | Not reviewed for this page |
| Cinchona bark | Quinine | Extracted, isolated and named in 1820 by Pelletier and Caventou; bark used against malaria from the 1600s | Qualaquin, FDA 2005 (NDA 021799) |
| Willow (bark salicylates) | Acetylsalicylic acid | Willow bark used as a painkiller and antipyretic for more than 3,500 years; synthesized by Bayer chemist Felix Hoffmann in 1897 | Not reviewed for this page |
| Galega officinalis (goat's rue) | Guanidine, galegine → metformin | Plant rich in guanidine, shown in 1918 to lower blood glucose; metformin first reported for diabetes by Jean Sterne in 1957 | Glucophage, FDA March 3, 1995 (NDA 020357) |
| Digitalis lanata | Digoxin | Extracted from the leaves (label) | NDA 009330, 1954; Lanoxin tablets NDA 020405, 1997, Type 7 |
| Colchicum autumnale | Colchicine | Used for gout for more than a millennium | Colcrys, FDA July 2009 (NDAs 022351, 022352), Type 7 |
Krishnamurti C, Rao SC. Indian J Anaesth 2016;60:861–862; Achan J, et al. Malar J 2011;10:144; Montinari MR, Minelli S, De Caterina R. Vascul Pharmacol 2019;113:1–8, abstract; Bailey CJ. Diabetologia 2017;60:1566–1576, abstract; Hadden DR. J R Coll Physicians Edinb 2005;35:258–260 (“metformin is derived from galegine”); Dasgeb B, et al. Br J Dermatol 2018;178:350–356, abstract; Kovács-Ábrahám Z, et al. Toxics 2026;14:309 (C. autumnale contains colchicine); Drugs@FDA submission classifications.
The organism gave the lead, not the supply
An approved drug that began in nature is often made another way. The labels below state how each drug substance is obtained today. Semi-synthesis starts from a harvested intermediate; total synthesis and peptide synthesis need no organism; fermentation grows the producing fungus.
| Drug | Natural origin | How the label describes the drug substance | Route |
|---|---|---|---|
| Paclitaxel | Taxus brevifolia | “obtained via a semi-synthetic process from Taxus baccata” | Semi-synthesis |
| Etoposide | Podophyllotoxin | “a semisynthetic derivative of podophyllotoxin” | Semi-synthesis |
| Eribulin | Halichondria okadai | “a synthetic analogue of halichondrin B, a product isolated from the marine sponge” | Total synthesis |
| Trabectedin | Tunicate | “a synthetic version of a substance that was originally extracted from a species of tunicate or ‘sea squirt’” (EMA) | Synthesis |
| Ziconotide | Conus magus | “a synthetic equivalent of a naturally occurring conopeptide”; 25 amino acids, three disulfide bridges | Peptide synthesis |
| Capsaicin (Qutenza) | Chili peppers | “a synthetic equivalent of the naturally occurring compound found in chili peppers” | Synthesis |
| Lovastatin | Aspergillus terreus | “isolated from a strain of Aspergillus terreus” | Fermentation |
| Cyclosporine | Beauveria nivea | “produced as a metabolite by the fungus species Beauveria nivea” | Fermentation |
| Digoxin | Digitalis lanata | “extracted from the leaves of Digitalis lanata” | Extraction |
| Vinblastine | Catharanthus roseus | “the salt of an alkaloid extracted from Vinca rosea Linn.” | Extraction |
Description sections (section 11 or “Description”) of the current US labels on DailyMed; EMA EPAR summary for Yondelis. “Route” is this page's classification of the label wording.
Medicines from the sea
The three marine-derived drugs in the table are made without harvesting. Ziconotide reproduces a cone-snail peptide that blocks N-type calcium channels and is given intrathecally. Eribulin is a synthetic analogue of halichondrin B, isolated from a sponge. Trabectedin, first isolated from a tunicate, was authorized in the EU in 2007 and by FDA in 2015.
Newman and Cragg note that a significant number of natural-product drugs and leads are produced by microbes, or by microbes interacting with the host from which they were isolated.
| Drug | Organism | Molecule | Approvals |
|---|---|---|---|
| Ziconotide (Prialt) | Cone snail, Conus magus | Peptide, C102H172N36O32S7, 2,639 Da | FDA December 28, 2004 |
| Trabectedin (Yondelis) | Tunicate | Alkylating drug, C39H43N3O11S, 761.84 Da | EU September 17, 2007; FDA October 23, 2015 |
| Eribulin (Halaven) | Sponge, Halichondria okadai | Halichondrin B analogue, mesylate salt 826.0 Da (free base 729.9) | FDA November 15, 2010 |
Prialt, Yondelis and Halaven labels (Description); Drugs@FDA NDAs 021060, 207953, 201532; EMA EPAR, Yondelis (authorization valid throughout the EU, September 17, 2007); Newman DJ, Cragg GM. J Nat Prod 2020;83:770–803, abstract.
Medicines from fungi, and red yeast rice
In 1928 Fleming saw a mold clear a staphylococcus plate; the mold was identified as Penicillium notatum, and the 1945 Nobel Prize went to Fleming, Chain and Florey. Akira Endo found compactin in Penicillium citrinum in 1972 and, in February 1979, monacolin K in Monascus ruber; the same year it proved identical to Merck's mevinolin from Aspergillus terreus, later named lovastatin.
FDA approved lovastatin as a new drug in 1987. Red yeast rice products with enhanced or added lovastatin therefore cannot be marketed as dietary supplements in the United States.
| Fungus | Molecule | Milestone |
|---|---|---|
| Penicillium notatum | Penicillin | Effect observed 1928; Nobel Prize 1945 |
| Penicillium citrinum | Compactin (ML-236B) | Found 1972 in a culture isolated from a rice sample from a Kyoto grain shop |
| Monascus ruber; Aspergillus terreus | Monacolin K = mevinolin = lovastatin | Both isolated February 1979; FDA approval August 31, 1987 (Mevacor) |
| Beauveria nivea | Cyclosporine, cyclic peptide of 11 amino acids | FDA November 14, 1983 (Sandimmune) |
Fleming A. Nobel lecture, December 11, 1945, and Nobel biography; Endo A. Proc Jpn Acad Ser B 2010;86:484–493; NCCIH (FDA position, warning letters); Drugs@FDA NDAs 019643 and 050573; Sandimmune label.
The four botanical drugs
A botanical drug keeps the plant mixture as the active ingredient instead of one purified molecule. FDA lists four approved as prescription drugs: three NDAs and one BLA. Each label defines the mixture by plant species, plant part and measured composition ranges, which is how batch-to-batch consistency is written into an approval.
| Drug | Plant and part | Drug substance, as the label defines it | FDA approval | Indication |
|---|---|---|---|---|
| Veregen (sinecatechins) ointment 15% | Camellia sinensis, leaf | Partially purified water extract; catechins 85–95% by weight, of which epigallocatechin gallate more than 55% | October 31, 2006 | External genital and perianal warts |
| Mytesi (crofelemer) 125 mg delayed-release tablet | Croton lechleri, red latex | Oligomeric proanthocyanidin mixture; average degree of polymerization 5 to 7.5 | December 31, 2012 | Non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy |
| NexoBrid (anacaulase-bcdb) topical gel | Ananas comosus, stem | Proteolytic enzyme mixture, 80–95% w/w proteins (stem bromelain, ananain, others) | December 28, 2022 (BLA) | Eschar removal in deep partial- and full-thickness thermal burns |
| Filsuvez (birch triterpenes) topical gel 10% | Betula pendula, B. pubescens and hybrids, bark | Refined dry extract: betulin 72–88%, lupeol 2.4–5.7%, betulinic acid 2.6–4.2%, erythrodiol 0.5–1.2%, oleanolic acid 0.3–0.8% (w/w) | December 18, 2023 | Wounds of dystrophic and junctional epidermolysis bullosa, 6 months and older |
FDA, “What is a Botanical Drug?” (content current as of September 3, 2026); Veregen, Mytesi, NexoBrid and Filsuvez labels (Description, Indications); Drugs@FDA NDAs 021902, 202292, 215064 and BLA 761192. Filsuvez: FDA Drug Trials Snapshot (EASE phase 3, NCT03068780, 223 patients at 49 sites in 26 countries); EU approval June 21, 2022.
What the record teaches
In 18 of the 22 approvals in the reference table, the active ingredient is one defined molecule or, for Coartem, a fixed pair; many of these are now made by semi-synthesis, synthesis or fermentation. The four botanical drugs kept the mixture and had to specify it by species, part and composition range. Lovastatin shows the reverse effect: a drug approved first keeps that molecule out of supplements.
| Observation | Evidence on this page |
|---|---|
| The extraction method can decide whether activity is seen | Cold ether extraction of A. annua gave consistent 100% parasite killing in animals where earlier extracts gave 12–40% (Nobel background) |
| Supply moves from harvest to synthesis or semi-synthesis | Paclitaxel, etoposide, eribulin, trabectedin, ziconotide, capsaicin labels |
| Few botanical mixtures have reached approval | Four approved under an NDA or BLA (2006–2023); FDA authors name CMC and efficacy as the obstacles |
| First lawful use decides the channel | Lovastatin approved as a drug in 1987; lovastatin-enhanced red yeast rice excluded from supplements (21 USC 321(ff)(3)(B); NCCIH) |
| Exclusivity ends and revenue follows | Taxol: US exclusivity to December 1997; sales down 25% in 2001 with generic competition |
Sources as cited in each section. Statute: 21 USC 321(ff)(3)(B). The claims a supplement may and may not make, and why, are on The claims gap.
Where EUTECNIQ would work
EUTECNIQ would apply the parts of this record that a botanical program controls: extraction conditions chosen by measurement, identity and composition ranges written as specifications, and early decisions on whether an ingredient belongs in the supplement or the drug channel. It has no drug programs, laboratory or data today.
Related pages: The claims gap · Pipeline · Extraction · Purification and standardization · History of botanical medicine · Natural vs synthetic
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.